Literature DB >> 3235217

Calcium dobesilate and its effects on hemorheology and microcirculation.

P Költringer1, O Eber, W Rothlauer, G Klima, P Lind, W Langsteger, P Wakonig.   

Abstract

In series, 50 patients suffering from cerebral (n = 33) and peripheral (n = 17) diseases were treated with 3 x 500 mg calcium dobesilate (Doxium) per day. Before onset of therapy and after 14 days the viscoelasticity of whole blood and plasma as well as hematocrit and microcirculation at the finger pad were measured. Viscoelasticity of whole blood, plasma and hematocrit decreased in a significant manner (p less than or equal to 0.001), while microcirculation increased significantly (p less than or equal to 0.001). The results justify the application of calciumdobesilate for ischemic diseases with elevated viscosity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3235217

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  2 in total

1.  Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI-1.

Authors:  Xiaoqian Zhang
Journal:  Exp Ther Med       Date:  2012-10-19       Impact factor: 2.447

Review 2.  Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids.

Authors:  Hervé Allain; Albert A Ramelet; Elisabeth Polard; Danièle Bentué-Ferrer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.